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Paratuberculosis (Johne’s disease) is a fatal disease of ruminants for which no effective treatment is avail-
able. Presently, no drugs against Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis), the caus-
ative agent of Johne’s disease, are approved for use in livestock. Additionally, M. paratuberculosis has been
linked to a human chronic granulomatous ileitis (Crohn’s disease). To assist in the evaluation of antimicrobial
agents with potential activity against M. paratuberculosis, we have developed a firefly luciferase-based assay for
the determination of drug susceptibilities. The microorganism used was M. paratuberculosis K-10(pYUB180),
a clinical isolate carrying a plasmid with the firefly luciferase gene. The MICs determined by the broth
macrodilution method were as follows: amikacin, 2 mg/ml; Bay y 3118, 0.015 mg/ml; clarithromycin, 1.25 mg/ml;
D-cycloserine, 25 mg/ml; ethambutol, 20 mg/ml; and rifabutin, 0.5 mg/ml. The strain was resistant to isoniazid
and kanamycin. The results obtained by the luciferase assay were identical or fell within 1 doubling dilution.
These results suggest that a combination of amikacin, clarithromycin, and rifabutin may be the most effica-
cious therapy for the treatment of M. paratuberculosis infections and that the use of fluoroquinolone class of an-
tibiotics deserves further consideration. We demonstrate that the luciferase drug susceptibility assay is reliable
for M. paratuberculosis and gives results within 7 days, whereas the broth macrodilution method requires 14 days.
Paratuberculosis (Johne’s disease) is an incurable, fatal dis-
ease of domestic and wild ruminants. Mycobacterium avium
subsp. paratuberculosis (M. paratuberculosis) is the etiologic
agent of this disease, which is manifested by chronic diarrhea
and weight loss. After months of diarrhea and wasting, the
affected animals either die or are culled (9, 11). In the United
States, the prevalence of M. paratuberculosis infection in dairy
and beef cattle herds has reached 34% in certain areas (12, 13)
and causes millions of dollars in lost revenue annually (35).
Furthermore, M. paratuberculosis has been tentatively linked to
Crohn’s disease, a chronic granulomatous ileitis of humans.
This disease mimics other mycobacterial infections in both an-
imals and humans (31). Evidence supporting the possibility
that M. paratuberculosis is the etiologic agent of Crohn’s dis-
ease include culture of this organism from intestinal tissue (11)
and amplification of the subspecies-specific IS900 sequence of
M. paratuberculosis from biopsy specimens by PCR (11, 21).
Currently, treatment of paratuberculosis in cattle is limited
to the extralabel use of therapeutic agents (29, 30), and no
antibiotic treatment is recommended for clinical cases of
Crohn’s disease. Even with a prolonged drug regimen, paratu-
berculosis in cattle is invariably fatal. A significant problem
hindering studies of the antimicrobial susceptibilities of this
organism is the long generation time of M. paratuberculosis and
the tendency of certain antibiotics to degrade during the eval-
uation period. Therefore, the objective of this study was to
develop a new assay that tests the drug susceptibilities of
M. paratuberculosis and that can be used to identify and screen
a very large number of compounds in less time. This technol-
ogy will facilitate the discovery of more powerful and less toxic
drugs than those currently available for the treatment of these
diseases. It is hoped that the development of this method,
which is amenable to high-throughput screens, will allow the
identification of compounds which will eventually result in
shorter and more effective treatments for Johne’s disease and
possibly Crohn’s disease.
Recently, methods for the assessment of the antimicrobial
susceptibilities of mycobacteria have used the luciferase gene
from Photinus pyralis, the American firefly; these methods have
been described elsewhere (1, 14, 15, 19, 20). This gene has
been introduced by transformation and phage infection into
slowly growing mycobacterial species, including M. paratuber-
culosis (14, 17, 20). The ability of an antimicrobial agent to
inhibit the growth of these strains can then be measured by
determining the decrease in bioluminescence. Here, we report
on the development of a firefly luciferase-based method for
determination of the drug susceptibilities of M. paratuberculo-
sis. For the development of this assay, we tested prototype
drugs from various classes of antimicrobial agents. Since there
is no standardized method for determination of the drug sus-
ceptibilities of mycobacteria except Mycobacterium tuberculo-
sis, we compared the luciferase-based assay with a previously
reported broth macrodilution assay used to determine the drug
susceptibilities of M. paratuberculosis (7).
MATERIALS AND METHODS
Bacterial strains and growth conditions. M. paratuberculosis K-10(pYUB180)
was grown in Middlebrook 7H9 broth with 0.05% Tween 80 and 0.5 mg of
mycobactin J (Allied Monitor, Fayette, Mo.) per ml at 37°C as described previ-
ously (17). The construction of the Escherichia coli-Mycobacterium spp. shuttle
plasmid pYUB180 has been described previously (20). This plasmid contains
both the firefly luciferase gene downstream from the Mycobacterium bovis BCG
hsp60 promoter (Phsp60) and a kanamycin resistance gene as a selectable marker.
All starter cultures used to inoculate test cultures were grown in the presence of
50 mg of kanamycin per ml to an optical density at 600 nm of 0.3 to 0.4. To create
an inoculum free of cellular clumping, 50 ml of cell culture was sonicated for 30 s
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with a Vibra-Cell model VC600 disrupter (Sonics and Materials, Inc., Danbury,
Conn.), passed through a 27-gauge needle three times, vortexed on high for 30 s,
and allowed to sit for a minimum of 5 min. The top 5 ml was then used for the
inoculation of cultures for MIC assays. Cell viability, as determined by BacLight
Bacterial Viability staining (Molecular Probes, Eugene, Oreg.), demonstrated
that 85% of the bacteria were viable after being subjected to this procedure. A
total of 50 ml of this prepared culture (ca. 7.5 3 106 CFU) was then inoculated
into each flask containing an antibiotic, and the cells were grown at 37°C.
Antimicrobial agents. Amikacin, D-cycloserine, ethambutol, kanamycin, and
isoniazid (all from Sigma Chemical Co., St. Louis, Mo.) and Bay y 3118 (gener-
ously donated by L. E. Bermudez and L. S. Young, Kuzell Institute, San Fran-
cisco, Calif.) were prepared in sterile deionized water. Rifabutin (Pharmacia Inc.,
Columbus, Ohio) and clarithromycin (Abbott Laboratories, Abbott Park, Ill.)
were prepared in dimethyl sulfoxide (Fisher Scientific, St. Louis, Mo.). All
further dilutions of each antibiotic were prepared in growth medium. The ranges
of concentrations tested were as follows: amikacin, 0.5 to 64 mg/ml; Bay y 3118,
0.008 to 100 mg/ml; clarithromycin, 0.625 to 80 mg/ml; D-cycloserine, 0.8 to 100
mg/ml; ethambutol, 1.25 to 160 mg/ml; isoniazid, 1.95 to 250 mg/ml; kanamycin, 1
to 128 mg/ml; and rifabutin, 0.03 to 4 mg/ml.
Broth macrodilution assays. Susceptibility testing was performed in triplicate
for each antimicrobial agent by following the guidelines of the National Com-
mittee for Clinical Laboratory Standards (22) with a total of eight twofold drug
dilutions in 10 ml of complete Middlebrook 7H9 broth with 0.05% Tween 80 and
0.5 mg of mycobactin J per ml. Each culture was grown in sterile 25-cm2 tissue
culture flasks, and for each antibiotic three flasks without antimicrobial agent
were included as controls. The MIC was defined as the minimum concentration
of the antimicrobial agent which inhibited growth at day 14.
Luminescence assays. Assays for bioluminescence were performed by trans-
ferring 100 ml of each growing culture into a separate 75-mm polystyrene test
tube (Sarstedt, Newton, N.C.) containing 250 ml of complete Middlebrook 7H9
broth without Tween 80. A total of 100 ml of 1 mM luciferin (Sigma) with 0.45
M sodium citrate (pH 5.0) was automatically injected into each tube, and the
bioluminescence was measured for 20 s without preset delay with an AutoLumat
LB953 luminometer (Wallac Instruments, Gaithersburg, Md.). Bioluminescence
was expressed as the number of relative light units (RLUs) detected in the
measurement period. RLUs were obtained by dividing the number of photoelec-
trons detected by 10, as specified by the manufacturer. The initial (day 0) RLUs
were measured within 30 min of inoculation. Other RLU outputs were measured
after 3, 7, and 14 days of incubation.
Definitions, calculations, and interpretation. The raw data that were obtained
were normalized by determining the initial and final ratios of test and control
RLUs for each antibiotic as described previously (27). Briefly, the initial light
output ratio was calculated as the ratio of test RLUs to control RLUs on day 0.
The final ratio was calculated as the ratio of test RLUs to control RLUs and was
determined individually for days 3, 7, and 14. Results for each time point were
then expressed as the percent relative change in bioluminescence, which was
calculated as follows: (final ratio/initial ratio) 3 100. The MIC was defined as the
lowest drug concentration that gave a relative change in bioluminescence of
#1.0% 1 0.5%. At these values, the bioluminescence of the sample is extin-
guished to less than 1% of the original light output at day 0.
RESULTS
Testing of susceptibility to selected antimycobacterial agents
by luciferase assays. The changes in the bioluminescence of
strain M. paratuberculosis K-10(pYUB180) in the presence of
each antimicrobial agent are shown in Fig. 1. Each graph
depicts the mean RLUs of three independent experiments for
each concentration of antibiotic after 3, 7, and 14 days of
incubation. Increases in RLUs could be observed by day 3
postinoculation in the presence of subinhibitory drug concen-
trations, thus reflecting an increase in the numbers of viable
bacteria. This trend continued through day 14 postinoculation,
with total RLUs increasing by 100- to 1,000-fold. For those
antibiotics with a discernible MIC, RLUs declined to back-
ground levels and remained at this level for all higher drug
concentrations.
The percent relative changes in bioluminescence for the
critical dilutions of each type of antibiotic are presented in
Table 1. Values of #1% 1 0.5% (100-fold extinction of biolu-
minescence compared with the bioluminescence for controls
containing no drug) were observed by day 7 for amikacin, Bay
y 3118, clarithromycin, D-cycloserine, ethambutol, and rifabu-
tin, with corresponding MICs of 16, 0.015, 1.25, 25, 20, and 0.5
mg/ml, respectively. For day 14, identical MICs could be de-
termined for clarithromycin, D-cycloserine, and rifabutin. The
MIC of amikacin was significantly lower (2 mg/ml), while the
MICs of Bay y 3118 and ethambutol were 0.008 and 10 mg/ml,
respectively, and were within 1 doubling dilution of the MIC
determined by day 7. Since for kanamycin and isoniazid the
percent relative change in bioluminescence remained well
above 1% for all dilutions through day 14, no MIC could be
determined for either of these antibiotics.
Comparison of the luciferase and broth macrodilution as-
says. The antimicrobial activities determined by the biolumi-
nescence assay at day 7 or 14 were closely correlated with those
determined by the broth macrodilution assay (determined at
day 14; Table 2). The MICs obtained by the luciferase assay at
day 7 and by the broth microdilution assay were identical for
Bay y 3118, clarithromycin, D-cycloserine, ethambutol, and ri-
fabutin but differed by 2 doubling dilutions for amikacin. At
day 14, the results of the luciferase assay were identical to
those of the broth macrodilution assay for amikacin, clarithro-
mycin, D-cycloserine, and rifabutin, but the results differed by
1 doubling dilution for Bay y 3118 and ethambutol. Strain
K-10(pYUB180) was resistant to isoniazid and kanamycin, and
no MIC within the concentration range tested could be deter-
mined by any of the methods.
To determine if an increase in the antibiotic concentrations
would inhibit bioluminescence without affecting the total num-
bers of viable bacteria, the CFUs over an entire 8-dilution
range were measured for a representative drug (amikacin). At
subinhibitory concentrations of antibiotic, no changes from
control values of either RLUs or CFUs were found (data not
shown). In the presence of the drug at the MIC, simultaneous
100-fold decreases in both RLUs and CFUs were observed,
with this correlation being maintained for the higher drug
concentrations. Therefore, decreasing RLUs reflected a corre-
sponding reduction in the number of viable bacteria. The ac-
tivity of a representative antibiotic against the wild-type strain
M. paratuberculosis K-10 was tested (amikacin) by the broth
macrodilution method to confirm that antimicrobial sensitivity
was not influenced by plasmid pYUB180. The MICs for K-10
and K-10(pYUB180) were identical (2 mg/ml) (data not
shown). The activity of kanamycin against strain K-10 was also
tested by the broth macrodilution method to confirm that the
kanamycin-resistant phenotype was conferred by pYUB180.
The resulting MIC of 1.25 mg/ml (data not shown) showed that
the wild-type strain of M. paratuberculosis K-10 was sensitive to
kanamycin.
DISCUSSION
Presently, no drugs are approved for the treatment of
Johne’s disease in livestock. Therefore, antibiotic therapy is
limited to the extralabel use of standard antimicrobial agents.
Various treatment regimens for the control of Johne’s disease
have been proposed, and these have had various levels of
success, but ultimately the disease is fatal to the animal. It is
hoped that the development of the assay described here will
allow the discovery of more effective and less toxic drugs. The
most commonly prescribed treatment regimen consists of iso-
niazid in combination with rifabutin and/or ethambutol, fol-
lowed by a daily dose of isoniazid for the duration of the
animal’s life (18, 30). Although isoniazid is used to treat infec-
tions caused by M. tuberculosis and M. bovis (23), the results
presented here indicate that isoniazid therapy may not be the
most effective treatment for M. paratuberculosis infections.
Further in vitro screening of antimicrobial agents is warranted.
Our data indicate that the luciferase-based MIC assay may
be applied for this purpose. It has the advantage that it re-
quires less time to obtain MIC data. Furthermore, the other
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method commonly used to determine M. paratuberculosis sus-
ceptibility is the BACTEC assay (33). However, this assay
requires a dedicated and specialized piece of equipment. In
contrast, the firefly luciferase assay can be performed with a
less expensive instrument such as a regular liquid scintillation
counter or a one-well luminometer.
An important consideration in mycobacterial drug suscepti-
bility assays is the use of Tween 80. Van Boxtel et al. (33)
observed that at concentrations of 0.1 to 1%, Tween 80 af-
fected colony morphology and caused cells to be more suscep-
tible to the tested drugs. A similar effect was observed with
strains of the M. avium complex (36). However, in a study with
strains of M. tuberculosis, M. bovis BCG, M. avium, and Myco-
bacterium intracellulare, it was shown that Tween 80 had a
significant effect on the MIC of rifampin but did not alter
the activities of the other antimicrobial agents tested (2). In
general, the absence of Tween 80 leads to considerable cell
clumping, introducing additional sources of variation for
FIG. 1. Bioluminescence of M. paratuberculosis K-10(pYUB180) after incubation for 3 (circles), 7 (squares), and 14 (triangles) days in broth cultures containing
different antimicrobial agents (A and B). Bioluminescence (RLU 3 0.001; y axis) is plotted against the drug concentration (in micrograms per milliliter; x axis). The
value for each time point is the mean of three independent experiments. Bars representing standard deviations are indicated. The mean bioluminescence of the cultures
immediately after inoculation (day 0) was 340 6 170.
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MIC determinations. In our experiments, we used Tween 80 at
a concentration of 0.05% so as to minimize both clumping of
cells and detergent-induced changes in drug susceptibility.
To demonstrate the applicability of the firefly luciferase as-
say in the determination of M. paratuberculosis drug suscepti-
bility, we selected eight prototype drugs inhibiting different
targets involved in basic bacterial processes. These processes
included inhibitors of cell wall biosynthesis (D-cycloserine, iso-
niazid, and ethambutol), protein synthesis (clarithromycin,
amikacin, and kanamycin), DNA supercoiling (Bay y 3118),
and RNA synthesis (rifabutin, a structural analog of rifampin
with higher levels of antimycobacterial activity). Amikacin, iso-
niazid, and rifampin have been suggested as therapeutic agents
for Johne’s disease (34). D-Cycloserine, ethambutol, clarithro-
mycin, and kanamycin are used as primary (ethambutol) or
second-line antimycobacterial agents in human medicine to
treat both M. tuberculosis and M. avium infections. Although
Bay y 3118 has no therapeutic use for the treatment of myco-
bacterial diseases in animals or humans due to its phototoxicity
(26), it was used as an example of the new types of fluoro-
FIG. 1—Continued.
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quinolones that are being developed and that have extended
activity against gram-positive organisms and high levels of in-
hibitory activity against mycobacteria (3, 4). Overall, M. para-
tuberculosis was sensitive to the majority of the antibiotics
tested. The drug susceptibilities determined by the biolumines-
cence method were similar to those determined by the broth
macrodilution method (Table 2). For most drugs, the MIC
obtained on day 7 by the bioluminescence method was identi-
cal to the value obtained by the broth macrodilution method.
Therefore, the bioluminescence assay provides a more rapid
determination of a drug’s effectiveness against M. paratubercu-
losis.
Individually, the activities of the antibiotics tested here cor-
related well with those described in previous reports on the
susceptibilities of mycobacteria to antimicrobial agents. Of the
studies reporting on the susceptibility of mycobacteria to D-
cycloserine, M. tuberculosis was susceptible to the drug at 25 to
75 mg/ml (25), whereas Mycobacterium sp. isolated from pa-
tients with Crohn’s disease were resistant to D-cycloserine at 5,
10, and 20 mg/ml (7). Our findings of a MIC of 25 mg/ml for
M. paratuberculosis are in contrast to those of Thorel and
coworkers (32), who reported that M. paratuberculosis strains
are resistant to D-cycloserine at 30 to 50 mg/ml in Middlebrook
7H11 agar. The results from those researchers may not be
comparable to our results due to methodological differences in
drug susceptibility assays. Wallace et al. (34) demonstrated
that for the M. avium complex, bacterial strains which are
resistant to a single fixed drug concentration in agar dilutions
are inhibited by lower concentrations of the same drug in broth
culture.
For ethambutol, our reported MICs of 10 mg/ml correlate
well with previous findings of MICs of 5 mg/ml for M. avium
and M. paratuberculosis (10, 15). Ethambutol is often pre-
scribed in combination with isoniazid. Both M. tuberculosis and
M. bovis are extremely sensitive to isoniazid, but non-M. tuber-
culosis mycobacteria are significantly more resistant to this
drug. M. paratuberculosis K-10(pYUB180) was resistant to iso-
niazid at $250 mg/ml. In previous reports, animal isolates of
M. paratuberculosis (8) and human isolates of Mycobacterium
sp. (10) were resistant to isoniazid at the single concentration
of 10 mg/ml. Similarly, Wallace et al. (34) demonstrated that
isolates of Mycobacterium marinum, M. avium complex, Myco-
bacterium smegmatis, and Mycobacterium chelonae were resis-
tant to isoniazid at 16 to .32 mg/ml, the highest concentrations
tested. Further studies are needed to elucidate if the high level
of resistance observed in our study is due to a strain variation
or if it is typical for most strains of M. paratuberculosis.
As expected, strain K-10(pYUB180) was resistant to kana-
mycin due to the production of the 39-aminoglycoside phos-
photransferase encoded by the Tn903-derived aph gene on
plasmid pYUB180. Amikacin is another deoxystraptamine ami-
noglycoside which is structurally similar to kanamycin, but it is
a poor substrate for the 39-aminoglycoside phosphotransferase
enzyme. Our MIC of 2 mg/ml and previous in vitro antimicro-
bial susceptibility results of 0.5 to 5 mg/ml for M. paratubercu-
losis (7) and Mycobacterium sp. (10) indicate that it is highly
effective against this mycobacterial species. Our results are in
contrast to those of Cooksey et al. (15), who reported that the
MIC of amikacin is .100 mg/ml for a recombinant strain of
M. avium carrying the same aph gene.
For Bay y 3118, our data indicated that M. paratuberculosis
was very sensitive, with an MIC of 0.015 mg/ml. This agrees
with other reports demonstrating MICs of 0.06 to 4 mg/ml for
M. tuberculosis (28), M. avium complex (4, 28), and non-M. tu-
berculosis mycobacterial species (3). Clarithromycin is indi-
cated for the treatment of human infections involving the
M. avium complex, usually in combination with amikacin, rifa-
butin, and ethambutol. The MIC of 1.25 mg/ml that we found
is slightly higher than the previously reported MICs of 0.25
TABLE 2. Comparison of broth macrodilution and
bioluminescence MICsa
Drug
Drug concn
range
(mg/ml)
Broth macro-
dilution MIC
(mg/ml)
Luciferase assay MIC
(mg/ml)
Day 7 Day 14
D-Cycloserine 0.8–100 25 25 25
Ethambutol 1.25–160 20 20 10
Isoniazid 1.95–250 $250 $250 $250
Bay y 3118 0.008–1.0 0.015 0.015 0.008
Amikacin 0.5–64 2 16 2
Kanamycin 1–128 $128 $128 $128
Clarithromycin 0.625–80 1.25 1.25 1.25
Rifabutin 0.03–4 0.5 0.5 0.5
a MICs were determined as described in Materials and Methods.
TABLE 1. Percent relative changes in bioluminescence for critical
concentrations of the antimicrobial agents tested
Antibiotic type and
antibiotic
Concn
(mg/ml)
Relative change in biolumines-
cence (%) on the
following daya:
3 7 14
Cell wall biosynthesis
inhibitors
D-Cycloserine 12.5 32.1 6 3.5 28.9 6 2.8 9.2 6 1.5
25b,c 2.3 6 0.5 0.4 6 0.1 <0.2
50 <0.2 <0.2 <0.2
Ethambutol 5 55 6 10 24 6 22 25.1 6 5.8
10c 18.4 6 3.9 2.2 6 0.5 <0.2
20b 7.9 6 1.9 1.1 6 0.4 <0.2
40 5.8 6 1.4 1.4 6 0.4 <0.2
Isoniazid 62.5 63 6 17 163 6 49 97 6 27
125 38 6 10 93 6 25 86 6 22
250 11.3 6 2.9 11.5 6 3.1 53 6 13
DNA supercoiling inhib-
itors, Bay y 3118
0.0 100 6 19 100 6 20 100 6 19
0.008c 39 6 42 4.5 6 5.7 0.7 6 0.8
0.015b 24.2 6 4.6 1.4 6 0.6 0.5 6 0.4
0.03 13.5 6 2.8 0.7 6 0.6 <0.2
Protein biosynthesis
inhibitors
Aminoglycosides
Amikacin 1 86.3 6 5.3 126 6 14 95 6 11
2c 52.0 6 8.0 65 6 11 0.4 6 0.3
4 15.4 6 1.4 8.1 6 0.9 0.6 6 0.9
8 7.2 6 1.3 1.9 6 0.3 0.2 6 0.2
16b 3.0 6 1.3 0.5 6 0.1 0.2 6 0.1
Kanamycin 32 91 6 32 91 6 31 429 6 150
64 83 6 29 99 6 34 453 6 151
128 56 6 19 68 6 25 220 6 100
Macrolide, clarithro-
mycin
0.625 34.7 6 7.2 68 6 23 18.3 6 3.2
1.25b,c 5.2 6 3.8 1.1 6 2.0 0.2 6 0.3
2.5 6.1 6 1.8 0.4 6 0.3 <0.2
Transcription inhibitors
Rifabutin 0.25 8.5 6 2.7 11.7 6 2.6 30.7 6 6.7
0.5b,c 6.0 6 1.6 0.5 6 0.3 0.2 6 0.2
1 5.1 6 1.6 0.2 6 0.1 <0.2
a Boldface type indicates a relative change in luminescence of #1.0% 1 0.5%.
b MIC for day 7.
c MIC for day 14.
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mg/ml for M. paratuberculosis (24) and 0.5 mg/ml for M. avium
(15). The rifamycin family of antibiotics has largely been re-
served for use in human medicine, so that its value as a treat-
ment in veterinary medicine may be underestimated. We re-
port the MIC to be 0.5 mg/ml, consistent with values of 0.06 to
0.5 mg/ml for M. avium (14, 15) and other mycobacterial spe-
cies (10).
Multiple-drug therapy is usually indicated for the treatment
of mycobacterial infections. In vivo results of combination ther-
apy against experimentally induced M. paratuberculosis in-
fections in animals are unavailable, but Fattorini et al. (16)
recently reported that monotherapy with isoniazid was ineffec-
tive in clearing M. avium infections in beige mice and that the
triple-drug combination of isoniazid-amikacin-clarithromycin
was the most effective. Of the drugs tested in our study, ami-
kacin, Bay y 3118, clarithromycin, and rifabutin had MICs of 2
mg/ml or lower. On the basis of these results, we recommend
that these classes of antibiotics be subjected to in vivo tests of
their activities against M. paratuberculosis infections.
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